178 related articles for article (PubMed ID: 15596872)
1. Comparison between glycoprotein IIb/IIIa blockade and distal protection device for the restoration of myocardial perfusion during percutaneous coronary intervention for acute myocardial infarction.
Mak KH; Phay C; Wong A; Kwok V; Tan KS; Lau KW; Koh TH
J Invasive Cardiol; 2004 Dec; 16(12):694-8. PubMed ID: 15596872
[TBL] [Abstract][Full Text] [Related]
2. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
[TBL] [Abstract][Full Text] [Related]
3. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.
Bajaj RR; Mohammad A; Hong T; Irfan A; Sharieff W; Bagnall A; Christie JA; Kutryk MJ; Chisholm RJ; Cheema AN
J Invasive Cardiol; 2010 Aug; 22(8):347-52. PubMed ID: 20679668
[TBL] [Abstract][Full Text] [Related]
4. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.
Danzi GB; Sesana M; Capuano C; Mauri L; Berra Centurini P; Baglini R
Am J Cardiol; 2004 Jul; 94(1):35-9. PubMed ID: 15219505
[TBL] [Abstract][Full Text] [Related]
5. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.
Costantini CO; Stone GW; Mehran R; Aymong E; Grines CL; Cox DA; Stuckey T; Turco M; Gersh BJ; Tcheng JE; Garcia E; Griffin JJ; Guagliumi G; Leon MB; Lansky AJ
J Am Coll Cardiol; 2004 Jul; 44(2):305-12. PubMed ID: 15261923
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
[TBL] [Abstract][Full Text] [Related]
7. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.
Desch S; Siegemund A; Scholz U; Adam N; Eitel I; de Waha S; Fürnau G; Lurz P; Wetzel S; Schuler G; Thiele H
Clin Res Cardiol; 2012 Feb; 101(2):117-24. PubMed ID: 22015616
[TBL] [Abstract][Full Text] [Related]
8. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
[TBL] [Abstract][Full Text] [Related]
9. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.
Maioli M; Zeymer U; van 't Hof AW; Gibson CM; Dudek D; Bellandi F; Noc M; Secco GG; Zorman S; Gabriel HM; Emre A; Cutlip D; Rakowski T; Gyongyosi M; Huber K; De Luca G;
J Invasive Cardiol; 2012 Jul; 24(7):324-7. PubMed ID: 22781470
[TBL] [Abstract][Full Text] [Related]
10. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA
Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177
[TBL] [Abstract][Full Text] [Related]
11. Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation).
De Luca G; Van't Hof AW; Gibson CM; Cutlip D; Zeymer U; Noc M; Maioli M; Zorman S; Gabriel HM; Emre A; Rakowski T; Gyongyosi M; Huber K; Bellandi F; Dudek D;
Am J Cardiol; 2015 Mar; 115(6):711-5. PubMed ID: 25655867
[TBL] [Abstract][Full Text] [Related]
12. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
[TBL] [Abstract][Full Text] [Related]
13. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention.
Bellandi F; Maioli M; Leoncini M; Toso A; Dabizzi RP
Int J Cardiol; 2006 Mar; 108(1):36-42. PubMed ID: 15927285
[TBL] [Abstract][Full Text] [Related]
14. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
Cura FA; Bhatt DL; Lincoff AM; Kapadia SR; L'Allier PL; Ziada KM; Wolski KE; Moliterno DJ; Brener SJ; Ellis SG; Topol EJ
Circulation; 2000 Jul; 102(1):28-34. PubMed ID: 10880411
[TBL] [Abstract][Full Text] [Related]
15. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.
Rakowski T; Siudak Z; Dziewierz A; Birkemeyer R; Legutko J; Mielecki W; Depukat R; Janzon M; Stefaniak J; Zmudka K; Dubiel JS; Partyka L; Dudek D
Am Heart J; 2009 Oct; 158(4):569-75. PubMed ID: 19781416
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shimada YJ; Nakra NC; Fox JT; Kanei Y
Am J Cardiol; 2012 Mar; 109(5):624-8. PubMed ID: 22152971
[TBL] [Abstract][Full Text] [Related]
17. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
[TBL] [Abstract][Full Text] [Related]
18. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R
J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002
[TBL] [Abstract][Full Text] [Related]
19. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction.
Raveendran G; Ting HH; Best PJ; Holmes DR; Lennon RJ; Singh M; Bell MR; Long KH; Rihal CS
Mayo Clin Proc; 2007 Feb; 82(2):196-202. PubMed ID: 17290727
[TBL] [Abstract][Full Text] [Related]
20. Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors.
De Luca G; Gibson MC; Hof AW; Cutlip D; Zeymer U; Noc M; Maioli M; Zorman S; Gabriel MH; Secco GG; Emre A; Dudek D; Rakowski T; Gyongyosi M; Huber K; Bellandi F;
J Cardiovasc Med (Hagerstown); 2013 Nov; 14(11):815-20. PubMed ID: 23519096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
